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Purpose
The SLE Subcommittee of the Childhood Arthritis and
Rheumatology Research Alliance (CARRA) is developing
standardized treatment plans for proliferative lupus
nephritis (LN) in childhood-onset SLE (cSLE) which will
serve as the basis for future comparative effectiveness stu-
dies. The Initial Delphi survey revealed wide variability in
the treatment of LN in cSLE. This abstract decribes the
process of developing standardized evidence-based induc-
tion treatment plans for LN in cSLE by using consensus
methods.
Methods
A consensus conference attended by 12 trainees and 42
voting members of the CARRA SLE Subcommittee was
conducted to discuss the components of the LN treat-
ment plan for which there was wide variability and poor
agreement. After the face-to-face conference, a second
online survey focusing on management aspects of the
induction therapy for LN was sent to the 42 voting
members of the SLE Subcommittee of CARRA to
resolve remaining issues. Consensus was defined at 70%.
Results
At the conference, two immunosuppressive treatment
options for the 6-month induction phase, cyclophospha-
mide and mycophenolate mofetil, were selected. Three
steroid regimens (primarily intravenous, primarily oral,
or mixed intravenous/oral) with corresponding tapering
schedules were developed to reduce variability in steroid
exposure [see Figure A] Consensus was attained on: a)
inclusion and exclusion criteria; b) primary and second-
ary outcome measures; and c) time-points for assessing
patient response. No consensus was reached on the fol-
lowing points: a) age cut-off for the definition of child-
hood-onset SLE; b) need for SLE-specific quality of life
measure; and c) measures of adherence to be utilized.
These are being addressed through subsequent surveys.
Conclusion
Several important consensus points were achieved in the
development of induction treatment plans for prolifera-
tive lupus nephritis in childhood-onset SLE. Further
refinement of these treatment plans and development of
plans for maintenance therapy are needed to allow their
use in future studies aimed at optimizing therapy for
lupus nephritis.
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